CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine

CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.

Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance

The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.

Biocon Biologics receives EU GMP Certification for its in Bengaluru

This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.

AMPEL BioSolutions' predicts drug options with RNA analytics & machine learning

Biosynth Carbosynth expands peptide offering with acquisition of Pepscan

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.

Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar

National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries

Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses

Wacker to build biotechnology center in Munich

The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements

HIL to commercialise VCRC Bti bio-larvicide technology for mosquito vector control programs

HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine